ST. LOUIS, March 26, 2019 /PRNewswire/ — WUGEN Inc., a biotechnology company developing a novel, universal allogeneic CAR-T therapy platform, today announced the […]
ST. LOUIS, Feb. 20, 2019 /PRNewswire/ — WUGEN Inc., a biotechnology company developing a novel, universal allogeneic CAR-T therapy platform, today announced data
ST. LOUIS, Dec. 3, 2018 /PRNewswire/ — WUGEN Inc., a biotechnology company developing a novel universal allogeneic CAR-T therapy platform, today announced
ST. LOUIS, Nov. 13, 2018 /PRNewswire/ — WUGEN Inc., a biotechnology company developing a novel universal allogeneic CAR-T therapy platform, today announced
ST. LOUIS, Nov. 1, 2018 /PRNewswire/ — WUGEN Inc., a biotechnology company developing a novel universal allogeneic CAR-T therapy platform, today announced
Leukemia, Cooper et al, February 2018
Biol Blood Marrow Transplant, Wagner et al, March 2017
Science Translational Medicine, Romee et al, September 2016
Biol Blood Marrow Transplant, Leong et al, April 2014
Blood, Romee et al, December 2012